Nations Financial Group Inc. IA ADV Invests $332,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nations Financial Group Inc. IA ADV purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 6,000 shares of the company's stock, valued at approximately $332,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $53,000. FMR LLC grew its position in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock worth $238,000 after purchasing an additional 3,379 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company's stock worth $241,000 after purchasing an additional 2,879 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $249,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock traded down $0.88 during mid-day trading on Friday, reaching $47.84. The company had a trading volume of 465,364 shares, compared to its average volume of 608,830. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.83 billion, a P/E ratio of -12.56 and a beta of 1.01. The business has a fifty day simple moving average of $51.97 and a 200 day simple moving average of $42.29.

Analysts Set New Price Targets

Several research firms recently issued reports on TARS. Guggenheim reiterated a "buy" rating on shares of Tarsus Pharmaceuticals in a research report on Monday, February 10th. The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research report on Friday, November 15th. Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Finally, Barclays increased their price target on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an "overweight" rating in a research report on Monday, January 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $56.00.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.